OPEN UP A WORLD
See how DUPIXENT reduced severe exacerbations, improved lung function, reduced or eliminated OCS use, and has a demonstrated safety profile.1-4
See the data in adult and pediatric patients
(12+ years)
OCS Reduction/Elimination
Only FDA-approved biologic
indicated for
OCS-dependent
asthma patients1
Not an actual DUPIXENT patient.
aSevere exacerbations were defined as deterioration of asthma requiring the use of SCS for at least 3 days or hospitalization or ED visit due to asthma that required SCS.1
bThrough Week 24 with DUPIXENT 300 mg Q2W + SOC (n=64) vs placebo + SOC (n=68) (0.20 vs 1.04; rate ratio: 0.19 [95% CI: 0.07, 0.56]) (baseline blood EOS ≥300 cells/µL, DRI12544, secondary endpoint).1
c470 mL improvement at Week 52 from baseline in pre-bronchodilator FEV1 with DUPIXENT 200 mg Q2W + SOC (n=264) vs 170 mL improvement with placebo + SOC (n=148) (baseline blood EOS ≥300 cells/µL, QUEST, secondary endpoint). ~72% of the total FEV1 improvement was seen after the first dose at Week 2.1,6
d75% of patients had improved ACQ-5 (asthma control) scores with DUPIXENT 200 mg Q2W + SOC vs 67% with placebo + SOC (OR: 1.46 [95% CI: 0.90, 2.35]) (baseline blood EOS ≥300 cells/µL, QUEST, secondary endpoint).1
e71% of patients had improved AQLQ(S) (quality of life) scores with DUPIXENT 200 mg Q2W + SOC vs 55% with placebo + SOC (OR: 2.02 [95% CI: 1.24, 3.32]) (baseline blood EOS ≥300 cells/µL, QUEST, secondary endpoint).1
fACQ-5 and AQLQ(S) were assessed as secondary endpoints but were ordered after the point at which the hierarchical break occurred. Results are descriptive.7
gThe asthma development program for patients aged 12 years and older included three randomized, double-blind, placebo-controlled, parallel-group, multicenter trials (DRI12544, QUEST, and VENTURE) of 24 to 52 weeks in treatment duration, which enrolled a total of 2888 subjects.1
See the data in pediatric patients (6-11 years)
Safety Data
Demonstrated safety profile in children with moderate-to-severe asthma1,4
SEE SAFETY DATAStudy Designs
Studied up to 1 year in over 400 children with moderate-to-severe asthma1
SEE STUDY DESIGNSNot an actual DUPIXENT patient.
ACQ-5, Asthma Control Questionnaire, 5-item version; AQLQ(S), Asthma Quality of Life Questionnaire, Standardized Version; ED, emergency department;
EOS, eosinophils; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; OCS, oral corticosteroid; OR, odds ratio; Q2W, once every 2 weeks; SCS, systemic corticosteroid; SOC, standard of care.